All times are listed in CET (Central European Time)

Browsing Over 190 Presentations

Sort By
Amgen - Precision medicine in NSCLC: Novel approaches for targeting KRAS Industry Satellite Symposium

Discussion and Q&A

Lecture Time
13:50 - 14:10
Speakers
  • A. Speakers (, Switzerland)
Session Name
Amgen - Precision medicine in NSCLC: Novel approaches for targeting KRAS
Room
Channel 2
Date
Fri, 26.03.2021
Time
12:50 - 14:20
Authors
  • A. Speakers (, Switzerland)
Amgen - Precision medicine in NSCLC: Novel approaches for targeting KRAS Industry Satellite Symposium

Drugging the undruggable: The science behind targeting KRAS

Lecture Time
12:50 - 13:10
Speakers
  • M. Barbacid (Madrid, Spain)
Session Name
Amgen - Precision medicine in NSCLC: Novel approaches for targeting KRAS
Room
Channel 2
Date
Fri, 26.03.2021
Time
12:50 - 14:20
Authors
  • M. Barbacid (Madrid, Spain)
Amgen - Precision medicine in NSCLC: Novel approaches for targeting KRAS Industry Satellite Symposium

Emerging KRAS-targeted therapies in NSCLC

Lecture Time
13:10 - 13:30
Speakers
  • M. Schuler (Essen, Germany)
Session Name
Amgen - Precision medicine in NSCLC: Novel approaches for targeting KRAS
Room
Channel 2
Date
Fri, 26.03.2021
Time
12:50 - 14:20
Authors
  • M. Schuler (Essen, Germany)
Amgen - Precision medicine in NSCLC: Novel approaches for targeting KRAS Industry Satellite Symposium

Incorporating KRAS as a novel biomarker: Challenges and opportunities

Lecture Time
13:30 - 13:50
Speakers
  • A. Ryska (Hradec Kralove, Czech Republic)
Session Name
Amgen - Precision medicine in NSCLC: Novel approaches for targeting KRAS
Room
Channel 2
Date
Fri, 26.03.2021
Time
12:50 - 14:20
Authors
  • A. Ryska (Hradec Kralove, Czech Republic)
Amgen - Precision medicine in NSCLC: Novel approaches for targeting KRAS Industry Satellite Symposium

Summary and close

Lecture Time
14:10 - 14:15
Speakers
  • M. Schuler (Essen, Germany)
Session Name
Amgen - Precision medicine in NSCLC: Novel approaches for targeting KRAS
Room
Channel 2
Date
Fri, 26.03.2021
Time
12:50 - 14:20
Authors
  • M. Schuler (Essen, Germany)
AstraZeneca - A European multidisciplinary perspective on evolving treatment practices in EGFRm NSCLC Industry Satellite Symposium

Welcome and Introduction

Lecture Time
16:30 - 16:34
Speakers
  • M. Perol (Lyon, France)
Session Name
AstraZeneca - A European multidisciplinary perspective on evolving treatment practices in EGFRm NSCLC
Room
Channel 3
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • M. Perol (Lyon, France)
AstraZeneca - A European multidisciplinary perspective on evolving treatment practices in EGFRm NSCLC Industry Satellite Symposium

Improving prognosis in patients with resected EGFRm NSCLC: A role for adjuvant EGFR-TKIs

Lecture Time
16:54 - 17:04
Speakers
  • M. Majem Tarruella (Barcelona, Spain)
Session Name
AstraZeneca - A European multidisciplinary perspective on evolving treatment practices in EGFRm NSCLC
Room
Channel 3
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • M. Majem Tarruella (Barcelona, Spain)
AstraZeneca - A European multidisciplinary perspective on evolving treatment practices in EGFRm NSCLC Industry Satellite Symposium

First-line EGFR-TKIs to improve patient outcomes in advanced EGFRm NSCLC

Lecture Time
17:04 - 17:14
Speakers
  • M. Perol (Lyon, France)
Session Name
AstraZeneca - A European multidisciplinary perspective on evolving treatment practices in EGFRm NSCLC
Room
Channel 3
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • M. Perol (Lyon, France)
AstraZeneca - A European multidisciplinary perspective on evolving treatment practices in EGFRm NSCLC Industry Satellite Symposium

Audience Q&A and panel discussion

Lecture Time
17:14 - 18:00
Speakers
  • A. Speakers (, Switzerland)
Session Name
AstraZeneca - A European multidisciplinary perspective on evolving treatment practices in EGFRm NSCLC
Room
Channel 3
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • A. Speakers (, Switzerland)
AstraZeneca - A European multidisciplinary perspective on evolving treatment practices in EGFRm NSCLC Industry Satellite Symposium

EGFR mutation testing in patients with resectable NSCLC: Challenges and considerations

Lecture Time
16:34 - 16:44
Speakers
  • J. Gosney (Liverpool, United Kingdom)
Session Name
AstraZeneca - A European multidisciplinary perspective on evolving treatment practices in EGFRm NSCLC
Room
Channel 3
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • J. Gosney (Liverpool, United Kingdom)
AstraZeneca - A European multidisciplinary perspective on evolving treatment practices in EGFRm NSCLC Industry Satellite Symposium

Optimising the patient journey in resectable EGFRm NSCLC: A Surgeon’s point of view

Lecture Time
16:44 - 16:54
Speakers
  • E. Bishay (Birmingham, United Kingdom)
Session Name
AstraZeneca - A European multidisciplinary perspective on evolving treatment practices in EGFRm NSCLC
Room
Channel 3
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • E. Bishay (Birmingham, United Kingdom)
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC Industry Satellite Symposium

Treating unresectable stage III NSCLC with immuno-oncology: A clinical case study

Lecture Time
16:45 - 17:00
Speakers
  • M. Reck (Grosshansdorf, Germany)
Session Name
AstraZeneca - Immuno-oncology treatment paradigms for first-line ES SCLC and unresectable stage III NSCLC
Room
Channel 1
Date
Thu, 25.03.2021
Time
16:10 - 17:40
Authors
  • M. Reck (Grosshansdorf, Germany)